Daniel Skovronsky on artificial intelligence
From ‘SCIENTIFIC BREAKTHROUGH’: FDA GREENLIGHTS Eli Lilly’s new oral drug · · Fox Business Clips
“We use artificial intelligence almost every task that we do in development. Unfortunately drug development takes a wrong time is expensive, 10 years billions of dollars just to create one new medicine. I don't know that AI radically changes that we are not going to be discovering drugs overnight but it allows us to reach higher go for harder diseases make drugs we thought never possible before.”
On , Daniel Skovronsky, Chief Scientific & Product Officer and President of Lilly Research Laboratories at Eli Lilly, spoke about artificial intelligence during ‘SCIENTIFIC BREAKTHROUGH’: FDA GREENLIGHTS Eli Lilly’s new oral drug on Fox Business Clips.
About Daniel Skovronsky
Daniel Skovronsky, Eli Lilly’s chief scientific and product officer, discussed the FDA approval of the company’s new oral GLP-1 drug, Founday, on Fox Business on May 10, 2026. He stated that the drug had received over 7,000 prescriptions in the U.S. within its first month and that phase three trial patients lost an average of 27 pounds. Skovronsky said he believes oral drugs are necessary to meet demand for obesity treatment, estimating that one billion people worldwide need such medicine but only about 20 million have been reached with injectables. He also noted that the company is investing $150 billion in facilities to produce the drug and others. Skovronsky also addressed Eli Lilly’s work on Alzheimer’s disease, saying that new diagnostic methods such as brain scans and blood tests can detect the disease before symptoms appear. He described the current era as a promising time for medical innovation, citing advances in genetics, engineered medicines, and artificial intelligence. Regarding healthcare costs, Skovronsky said data shows treating obesity can reduce overall healthcare spending, and he encouraged patients to speak with their employers about ensuring drug coverage.